GlassScriptPhysician profile
Ramiro De Leon
NPI 1467736868
$4,655.44
in general payments reported to CMS, 2019-2025
32 companies · $682 in 2025
The $682 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $892 · 2022: $832 · 2023: $1,302 · 2024: $947 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,931.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,105.32 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $871.51 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $477.58 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $224.04 | 2021-2025 | Farxiga, Airsupra |
| Amgen INC. | $223.35 | 2021-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $156.91 | 2021-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.30 | 2021-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $143.79 | 2021-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $129.34 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $126.67 | 2021-2024 | Xarelto |
| Optinose US, INC. | $124.91 | 2022 | |
| Pfizer INC. | $109.25 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.85 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $87.49 | 2022-2025 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $86.46 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $67.64 | 2021 | |
| Phathom Pharmaceuticals, INC. | $61.49 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $58.10 | 2024-2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $48.45 | 2022-2023 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $46.53 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $40.73 | 2023-2025 | Rexulti |
| Phadia US INC. | $39.38 | 2023-2024 | Immunocap |
| Sanofi-Aventis U.S. LLC | $32.05 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.39 | 2022 | |
| Averitas Pharma INC. | $23.15 | 2024 | Qutenza |
| Exact Sciences Corporation | $18.50 | 2024 | Cologuard Collection Kit |
| Antares Pharma, INC. | $16.69 | 2024 | Xyosted |
| Astellas Pharma US INC | $15.62 | 2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $13.84 | 2022 | |
| Esperion Therapeutics, INC. | $13.10 | 2021 | |
| Paratek Pharmaceuticals, INC. | $12.65 | 2021 | |
| Genentech USA, INC. | $8.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramiro De Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.